Strategic Growth Zelluna is advancing an allogeneic off-the-shelf TCR-NK platform targeting solid tumors with a lead candidate entering clinical trials in 2026, representing a compelling opportunity for CDMO partners, large biotech collaborators, and investors seeking early access to innovative cell therapies.

Manufacturing Readiness The company emphasizes scalable, cost‑effective manufacturing with broader patient accessibility potential, signaling a need for manufacturing partners and process development support to satisfy future clinic and commercial demand.

Partnership Potential Recent collaborations and service needs (Catalent partnership for process development and manufacturing) highlight open avenues for CRO/CDMO engagements, supply agreements, and technical collaborations to accelerate development timelines.

Financial Timeline With a modest revenue base and a $13M funding level alongside leadership changes in 2025, Zelluna may seek strategic investments, licensing deals, or co-development arrangements to scale operations and fund clinical programs.

US & Global Reach Expansion efforts and US presence bolstered by leadership hires indicate an opportunity to partner on regulatory strategy, regional manufacturing, and clinical trial execution in key markets, aligning with potential global alliance discussions.